Enzymatica AB Share Price Nasdaq Stockholm
Equities
SE0003943620
Pharmaceuticals
Sales 2024 * | 6M 65.01M 501M | Sales 2025 * | 11.54M 125M 964M | Capitalization | 50.24M 545M 4.19B |
---|---|---|---|---|---|
Net income 2024 * | -4M -43.37M -334M | Net income 2025 * | -1M -10.84M -83.49M | EV / Sales 2024 * | 8.79 x |
Net Debt 2024 * | 2.46M 26.68M 205M | Net cash position 2025 * | 1.65M 17.86M 138M | EV / Sales 2025 * | 4.21 x |
P/E ratio 2024 * |
-12.1
x | P/E ratio 2025 * |
-20.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.79% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 01/07/01 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 18/17/18 |
Director of Finance/CFO | 55 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 19/16/19 |
Director/Board Member | 56 | 15/16/15 | |
Director/Board Member | 57 | 01/21/01 |
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |